Bifidobacterium catenulatum boosts anti-PD-1 efficacy in microsatellite stable colorectal cancer via activating CD8+ T cells - PubMed
6 hours ago
- #Immunotherapy
- #Microbiome
- #Colorectal Cancer
- Bifidobacterium catenulatum is depleted in colorectal cancer (CRC) patients compared to healthy controls.
- Oral administration of B. catenulatum inhibits tumor growth in multiple CRC mouse models.
- B. catenulatum synergizes with anti-PD-1 therapy in microsatellite stable (MSS) CRC by enhancing CD8+ T cell infiltration.
- The beneficial effect is mediated by acetate, a metabolite from B. catenulatum, which activates CD8+ T cells via MCT-4 and MAPK signaling.
- B. catenulatum is a potential adjuvant to improve immunotherapy efficacy against colorectal cancer.